271 related articles for article (PubMed ID: 17251223)
1. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
3. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
Cugno M; Ingegnoli F; Gualtierotti R; Fantini F
Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
5. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
7. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Puttevils D; De Vusser P; Geusens P; Dens J
Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
[TBL] [Abstract][Full Text] [Related]
8. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
Toussirot É
Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
[TBL] [Abstract][Full Text] [Related]
9. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
[TBL] [Abstract][Full Text] [Related]
10. The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature.
Sattin M; Towheed T
Curr Rheumatol Rev; 2016; 12(3):208-222. PubMed ID: 27041084
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Nurmohamed MT; van Halm VP; Dijkmans BA
Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.
Radovits BJ; Kievit W; Laan RF
Drugs Aging; 2009; 26(8):647-64. PubMed ID: 19685931
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease in rheumatoid arthritis.
Gonzalez-Gay MA; Gonzalez-Juanatey C; Miranda-Filloy JA; Garcia-Porrua C; Llorca J; Martin J
Biomed Pharmacother; 2006 Dec; 60(10):673-7. PubMed ID: 17049201
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.
Barnabe C; Martin BJ; Ghali WA
Arthritis Care Res (Hoboken); 2011 Apr; 63(4):522-9. PubMed ID: 20957658
[TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis].
Kleinert S; Krueger K
Z Rheumatol; 2011 Aug; 70(6):464-72. PubMed ID: 21863467
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
Pieringer H; Pichler M
QJM; 2011 Jan; 104(1):13-26. PubMed ID: 21068083
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis.
Manfredi AA; Baldini M; Camera M; Baldissera E; Brambilla M; Peretti G; Maseri A; Rovere-Querini P; Tremoli E; Sabbadini MG; Maugeri N
Ann Rheum Dis; 2016 Aug; 75(8):1511-20. PubMed ID: 26819099
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Manifestations in Rheumatoid Arthritis.
Sanghavi N; Ingrassia JP; Korem S; Ash J; Pan S; Wasserman A
Cardiol Rev; 2024 Mar-Apr 01; 32(2):146-152. PubMed ID: 36729119
[TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.
Luciano N; Barone E; Timilsina S; Gershwin ME; Selmi C
Clin Rev Allergy Immunol; 2023 Dec; 65(3):403-419. PubMed ID: 38157095
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
